Biotech entity

Baldwin

Company BWIN

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Crinetics Pharmaceuticals, the most common co-covered peer. The tracked stories average 3 original sources each. Baldwin appears in 1 tracked Biotech story from February 27, 2026.

Last mentioned: Feb 27, 2026

Entity pulse

Recent coverage · Baldwin

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Baldwin

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Crinetics Pharmaceuticals, the most common co-covered peer. The tracked stories average 3 original sources each. Baldwin appears in 1 tracked Biotech story from February 27, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Baldwin. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. NDA Submission

    Planned submission of paltusotine New Drug Application to the FDA.

  2. Phase 3 Initiation

    Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.

  3. Earnings Call

    Management confirms commercial readiness and pipeline acceleration.

  4. PATHFNDR-2 Success

    Completion of Phase 3 trial for paltusotine in acromegaly with positive results.

Stories mentioning Baldwin 1

Pharma Neutral

Crinetics Signals Commercial Readiness as Lead Candidates Near FDA Submission

Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.

3 sources

Baldwin is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.